Neuron Pharmaceuticals has announced first half 2023 highlights in its exploration of ibenamide as a treatment for treatment-resistant schizophrenia (TRS).
In its report, the company reviewed the results of Study 014/015, the first international trial of an antipsychotic novel chemical entity (NCE) as an add-on to a single antipsychotic in patients with TRS. The study results showed that ibnamide was safe, well tolerated among participants at all doses, and had a very low incidence of treatment-emergent adverse events.1
Overall, 97% of Study 014 participants completed 6 weeks of treatment, and more than 90% of participants who completed treatment chose to continue Study 015 treatment.The company has presented this data at several international psychiatric conferences and this data was published in International Journal of Neuropsychopharmacology in june.1
Neuron also announced that it is currently developing a follow-up study evaluating ibenamide in patients with TRS and chronic schizophrenia. The Company is conducting a multinational, randomized, double-blind, 12-week, placebo-controlled trial to further investigate the safety, tolerability and efficacy of ibenamide (15/30 mg twice daily) as an add-on. Working on the start of 003. Treatment of TRS patients.1
Evamide (30 mg twice daily) has also been evaluated as a treatment for patients with chronic schizophrenia in Study 008A, a 4-week, randomized, double-blind, placebo-controlled study. The full results of Study 008A are expected to be published in late 2023 or early 2024.1
Read the full 2023 first half report here.
1. Neuron will release results for the first half of 2023 to provide an update on its research and development. Neuron Pharmaceutical. news release. August 4, 2023. Accessed 22 August 2023. https://www.newron.com/news-and-media/regulatory-news/newron-announces-h1-2023-results-and-provides-rd-update